Latanoprost Ratiopharm Italia (Latanoprost)

• Latanoprost is a prostaglandin analog used to lower intra‑ocular pressure in glaucoma‑related conditions.
• Open‑angle glaucoma: lowers intra‑ocular pressure to slow disease progression.
• Ocular hypertension: reduces eye pressure to prevent development of glaucoma.
• Pseudoexfoliative glaucoma: improves aqueous outflow and controls pressure in this secondary open‑angle form.

• Latanoprost binds to prostaglandin F (FP) receptors in the ciliary body, activating a cascade that remodels the extracellular matrix of the uveoscleral pathway. This enhances uveoscleral outflow of aqueous humor, thereby decreasing intra‑ocular pressure and helping to protect the optic nerve from pressure‑related damage.

Latanoprost may cause ocular and peri‑ocular changes, most of which are mild and reversible.

Common Side Effects

• Eye redness: mild conjunctival hyperemia.
• Increased eyelash growth: longer, thicker lashes.
• Iris darkening: gradual brownish pigmentation.
• Eye irritation: foreign‑body sensation or mild discomfort.
• Blurred vision: transient visual disturbance after instillation.
• Periocular skin darkening: mild hyperpigmentation of the eyelid skin.

Serious or Rare Side Effects

• Severe eye inflammation: uveitis or iritis requiring medical attention.
• Allergic reaction: swelling, itching, or rash around the eye.
• Vision changes: sudden loss of vision or visual field defects.
• Ocular infection: signs of bacterial or fungal infection.
• Periorbital fat atrophy: noticeable hollowing around the eye.
• Corneal edema: swelling of the cornea affecting clarity.

• Before using Latanoprost, consider the following safety measures.
• Monitor intra‑ocular pressure: ensure adequate pressure reduction.
• Avoid use in active ocular infection: may exacerbate infection.
• Caution with uveitis history: can worsen intra‑ocular inflammation.
• Use carefully in corneal abnormalities: may affect drug absorption.
• Pregnancy and breastfeeding: safety not established; weigh risks and benefits.
• Store at room temperature: keep bottle tightly closed, protect from light and moisture.

Latanoprost can interact with other ocular or systemic agents; awareness helps prevent adverse outcomes.

Major Interactions (Avoid)

• Concurrent prostaglandin analogs: additive ocular irritation.
• Systemic carbonic anhydrase inhibitors: excessive IOP lowering.
• Topical ocular anesthetics: increased corneal toxicity.

Moderate Interactions (Monitor Closely)

• Topical corticosteroids: may reduce latanoprost efficacy.
• Contact lens wear: potential drug adsorption on lenses.
• Systemic beta‑blockers: additive systemic hypotensive effect.
• Other IOP‑lowering drops: monitor for over‑reduction of pressure.